Clinical trial · Interventional
Interventional X-ray and Scintigraphy Imaging of 99mTc-MAA During the Radioembolisation Pretreatment Procedure
NCT06013774CI-TRIAL-00069110IXSIcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To establish the safety and feasibility of interventional x-ray and scintigraphy imaging during the pre-treatment procedure of hepatic radioembolization
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IXSI | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Hybrid imaging during the pre-treatment procedure of radioembolization
- description
- Hybrid imaging will be performed on patients undergoing the pre-treatment procedure of radioembolization
- interventionNames
- Device: IXSI
Primary outcomes (1)
- measure
- Device Feasibility
- timeFrame
- Immediately after surgery
- description
- The feasibility of IXSI will be assessed by questionnaires filled in by interventional radiology personnel
Secondary outcomes (2)
- measure
- Radioactivity distribution over time
- timeFrame
- Immediately after surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Participants must have given written informed consent and comply with the requirements of the study protocol. 2. Must be aged 18 years or over. 3. Must be selected to undergo a 99mTc-MAA procedure as part of their radioembolisation treatment. 4. Sufficiently fit to undergo an additional examination time of 30-90 minutes. 5. Have a CT acquired less than 6 weeks before the pre-treatment radioembolisation procedure. Exclusion Criteria: 1. Patients expected to require more than two injection positions for radioembolisation treatment. 2. Pregnancy or nursing. 3. Patients suffering from psychic disorders that make a comprehensive judgement impossible, such as psychosis, hallucinations and/or depression. 4. Patients who are declared incompetent. 5. Previous enrollment in the present study 6. Claustrophobia 7. The last dose of prior chemotherapy has been received less than weeks prior to the planned 99mTc-MAA pre-treatment procedure. 8. Radiation therapy within the last 4 weeks before the planned 99mTc-MAA pre-treatment procedure 9. Major surgery within the last 4 weeks prior to the planned 99mTc-MAA pre-treatment procedure 10. Any unresolved toxicity greater than Common Terminology Criteria for Adverse Events (CTCAE version 5) grade 2 from previous anti-cancer treatment 11. Body weight over 250 kg (because of maximum table load) 12. Patient length over 1.90 m (to fit IXSI geometry) 13. Patient bust line over 135 cm (to fit IXSI geometry)
References
Publications (1)
- DERIVEDDietze MMA, Meddens MBM, van Rooij R, Braat AJAT, de Keizer B, Bruijnen RCG, Lam MGEH, Smits MLJ, de Jong HWAM. Safety and Feasibility of Interventional Hybrid Fluoroscopy and Nuclear Imaging in the Work-up Procedure of Hepatic Radioembolization. Radiol Imaging Cancer. 2024 Nov;6(6):e240044. doi: 10.1148/rycan.240044. PMID 39485113